Goldman Sachs Series Highlights AI’s Role in Industry Transformation
- •Xaira Therapeutics CEO explains how AI accelerates drug discovery and molecular research.
- •Glean and Databricks founders discuss AI’s impact on enterprise productivity and data infrastructure.
- •Business leaders highlight the shift from theoretical AI to practical, high-impact industry implementation.
The Goldman Sachs "Talks at GS" series recently featured a collection of deep-dive conversations with tech visionaries, highlighting how artificial intelligence is moving beyond theoretical potential into tangible industry disruption. One standout session features Marc Tessier-Lavigne, CEO of Xaira Therapeutics, who explains how advanced models are now being used to predict molecular interactions, significantly shortening the timeline for drug discovery and development in the biotech sector.
In the enterprise space, Arvind Jain of Glean and Ali Ghodsi of Databricks discussed what they term the "Enterprise Revolution." They emphasized that the true power of AI in business lies in its ability to organize and retrieve internal knowledge—a concept often referred to as search-driven productivity—and how companies are rebuilding their data infrastructure to support large-scale foundation models.
These dialogues underscore a broader shift where AI is no longer a standalone feature but the core engine for modern innovation. From streamlining clinical trials in healthcare to optimizing complex financial workflows, the series illustrates that the current AI supercycle is driven by leaders who can bridge the gap between advanced research and practical applications across global markets. The focus remains on how these technologies can solve specific, high-value problems rather than just providing general automation.